Market Place
Sourcing Support
Mitsubishi Tanabe Presents Radicava® Ph 3 Results At NEALS 2024
21 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma Unveils New ALS Findings At NEALS 2024
17 Oct 2024 //
PR NEWSWIRE
Mitsubishi America to Showcase ALS Research at 2024 AANEM Meeting
15 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Presents RADICAVA ORS Data At AMCP Nexus
10 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe To Present Radicava ORS® Data At NASP Meeting
06 Oct 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Presents Ph 3 Data of ND0612 In Parkinson
30 Sep 2024 //
PR NEWSWIRE
Mitsubishi Tanabe To Showcase RADICAVA ORS® Presentations At Meeting
17 Sep 2024 //
PR NEWSWIRE
Mitsubishi Tanabe To Present At American Neurological Association Meeting
12 Sep 2024 //
PR NEWSWIRE
Mitsubishi To Present RADICAVA ORS Real-World Data At ALS Conference
09 Jul 2024 //
PR NEWSWIRE
Moderna And Mitsubishi Tanabe Partner For mRNA Vaccines In Japan Market
08 Jul 2024 //
ACCESSWIRE
Mitsubishi Tanabe Pharma To Present Parkinson`s Research At 10th EAN Congress
28 Jun 2024 //
PR NEWSWIRE
Acquisition Of Argatroban Business In Europe
17 Jun 2024 //
PRESS RELEASE
Mitsubishi Tanabe Presents RADICAVA® Results For ALS At ENCALS 2024
17 Jun 2024 //
PR NEWSWIRE
Mitsubishi Tanabe: Highlighting ALS Research At ENCALS 2024
05 Jun 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America, Inc. (MTPA) Stands with the ALS Community
23 May 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Presents At Parkinson`s Congress
16 May 2024 //
PR NEWSWIRE
USD 10.8 Million Investment for Malaria and NTDs Drug Development
08 May 2024 //
PR NEWSWIRE
Mitsubishi Tanabe To Present RADICAVA ORS® Real-World Data
03 May 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
29 Apr 2024 //
PR NEWSWIRE
Mitsubishi Tanabe: RADICAVA® ALS Healthcare Resource Use At AMCP
15 Apr 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Neuro Research At AAN 2024
12 Apr 2024 //
PR NEWSWIRE
MTP America Receives U.S. FDA Orphan Drug Exclusivity for RADICAVA
08 Apr 2024 //
PR NEWSWIRE
Mitsubishi Tanabe America gets US FDA orphan drug exclusivity Radicava ORS
08 Apr 2024 //
PHARMABIZ
Mitsubishi Tanabe Announces Publication of Positive Results from Ph 3 of ND0612
18 Mar 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson`s Disease
04 Mar 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research
01 Mar 2024 //
PR NEWSWIRE
Mitsubishi Tanabe Announces Presentations in ALS at 34th International Symposium
05 Dec 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Spotlights ALS Research
16 Oct 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Showcases Depth of ALS Research
04 Oct 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Presents Positive Results from Pivotal Phase 3
29 Aug 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Announces Presentations in Parkinson`s Disease at 2023
28 Aug 2023 //
PR NEWSWIRE
Mitsubishi Announces Analysis Examining Effect of Intervention with RADICAVA
17 Aug 2023 //
PR NEWSWIRE
Mitsubishi Tanabe America Highlights Latest Research in Parkinson`s Disease
05 Jul 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma Celebrates One-Year Anniversary of RADICAVA ORS
15 Jun 2023 //
PR NEWSWIRE
Mitsubishi Tanabe America to Partner with ALS Natural History Study Consortium
06 Jun 2023 //
PR NEWSWIRE
Mitsubishi Tanabe America Announces Presentations at XXVIII World Congress
12 May 2023 //
PR NEWSWIRE
Mitsubishi Tanabe to Present Latest Findings Across ALS & PD at 2023
20 Apr 2023 //
PR NEWSWIRE
Eli Lilly and Mitsubishi Tanabe launch new diabetes treatment in Japan
18 Apr 2023 //
BIOSPECTRUM ASIA
Mitsubishi Tanabe Announces Reorganization and Appoints New Leadership
03 Apr 2023 //
PR NEWSWIRE
Mitsubishi TAnnounces Enrollment Completion for Phase 3b Study of RADICAVA ORS
23 Mar 2023 //
PR NEWSWIRE
Mitsubishi Tanabe America to Share ALS Research at AMCP Annual Meeting 2023
20 Mar 2023 //
PR NEWSWIRE
Tanabe Pharma Announces 10,000 People with ALS Treated with RADICAVA ORS
16 Mar 2023 //
PR NEWSWIRE
RADICAVA ORS Added to U.S. Department of Veterans Affairs National Formulary
10 Mar 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Announces 48-Week Results from Global
27 Feb 2023 //
PR NEWSWIRE
UiPath Helps Mitsubishi Tanabe Pharma Accelerate Business Operational Efficiency
23 Feb 2023 //
BUSINESSWIRE
Mitsubishi Announces 4,000 ALS Patients in Have Been Treated with RADICAVA ORS
26 Jan 2023 //
PR NEWSWIRE
Mitsubishi Tanabe Pharma America Announces Presentations at ALS/MND
06 Dec 2022 //
PRNEWSWIRE
Mitsubishi Presents Data from REFINE-ALS Biomarker Study at NEALS Meeting
02 Nov 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Data at 21st
01 Nov 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma America Presents Data on RADICAVA ORS
21 Sep 2022 //
PRNEWSWIRE
ICER panel says two ALS drug candidates have `low` long-term value
20 Aug 2022 //
ENDPTS
Mitsubishi Tanabe Announces Real-World Data Analysis of Survival with RADICAVA
15 Aug 2022 //
PRNEWSWIRE
Mitsubishi Tanabe models economic impact of IV-to-oral switch
02 Aug 2022 //
FIERCEPHARMA
Japan`s EditForce & Mitsubishi ink gene therapy deal for ¥20 B
05 Jul 2022 //
BIOSPECTRUMASIA
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
05 Jul 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Pharma America Shows Long-Term Results of RADICAVA PMS Study
29 Jun 2022 //
PRNEWSWIRE
RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS
15 Jun 2022 //
PRNEWSWIRE
Mitsubishi Tanabe Presents 48-Week Result from PIII Safety Study of RADICAVA ORS
01 Jun 2022 //
PRNEWSWIRE
FDA Approves RADICAVA ORS Oral Suspension for ALS by Mitsubishi Tanabe
26 May 2022 //
PRNEWSWIRE
Mitsubishi’s Oral Radicava Provides Convenience Option For ALS
14 May 2022 //
THE SCRIP
